Drug intelligence / Profile preview

SFA-009

Development stage: Preclinical
Lead developer: SFA Therapeutics
Modality: Small Molecules

Overview

SFA-009 is a small molecule drug candidate developed by SFA Therapeutics as an adjunct treatment for pancreatic cancer. It is derived from natural substances produced in the human microbiome and leverages the company's proprietary SFA technology platform. The drug is designed to be used in conjunction with existing pancreatic cancer therapies, potentially offering a novel approach to improving outcomes in this challenging disease. As of June 2025, SFA-009 remains in preclinical development and has not yet entered clinical trials[1][2][3][4].

Beyond the preview

Go deeper on SFA-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SFA-009.

Explore the full profile